Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.


Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Independent Medical Education Funding and Application

As part of Amgen's mission to further the advancement of medicine and healthcare, Amgen supports Independent Medical Education ("IME"). IME is professional education given by accredited medical education providers who design and implement programs totally independent of any Amgen influence, as defined by standards such as the Accreditation Council for Continuing Medical Education ("ACCME") guidelines, the FDA's Guidance: Industry Supported Scientific and Educational Activities, and the PhRMA Code.

Funding requests including for live presentations, written enduring materials, online courses, and conference symposia from organizations (e.g. hospitals, universities, societies, medical-education vendors) will be reviewed and assessed in conjunction with Amgen's goal to help physicians and other healthcare professionals to obtain information and insights that contribute to the improvement of patient care and the advancement of medicine.

Areas of Interest to Amgen

Click to Expand

Amgen supports IME that address:

  • education of health care providers including trainees, allied health professionals and payers
  • advancing the understanding of the disease state
  • improving health care providers' understanding of the diagnosis, treatment, outcomes, and co-morbidities
  • quality, reimbursement, access to care
  • Innovative and biosimilar drug development

Disease States and Areas of Interest:

Biomedical Data Sciences


  • Burden of disease and clinical consequences of osteoporotic fractures
  • Improving awareness, diagnosis and treatment of osteoporosis
  • Identification of patients with osteoporosis at high risk for fracture
  • Conditions other than Post- Menopausal Osteoporosis/Male Osteoporosis associated with bone loss and fractures: Osteogenesis Imperfecta, Glucocorticoid-Induced Osteoporosis, Hypogonadism, Vitamin D deficiency, malabsorption
  • Use of non-invasive techniques to assess bone quality


Dyslipidemia education to increase awareness and (if applicable) consequences of:

  • Treatment of atherosclerosis and unmet needs
  • Familial Hypercholesterolemia – diagnosis, treatment
  • Atherogenic states (High LDL, Raised Lipoprotein(a), Low High-Density Lipoprotein (HDL), Elevated LDL particle number/apo B/non-HDL
  • Statin-intolerance
  • LDL management in high-risk individuals and the impact to payors and hospitals
  • Cardiovascular risk in Coronary Artery Disease and other high CV risk populations
  • Role of PCSK9 in regulation of LDL and in vascular biology

Heart Failure education to increase awareness of:

  • Acute and chronic heart failure, their treatment options and unmet needs (e.g., special populations, renal insufficiency, indwelling cardiac devices)
  • Treatment paradigms for Heart Failure beyond the neurohormonal hypothesis
  • Research efforts around  Heart rate and cardiovascular risk in heart failure, genetic biomarkers of cardiovascular risk in heart failure,  pharmacogenomics of the treatment response in  heart failure
  • Relationship between heart rate and cardiovascular risk in heart failure
  • Prognosis for patients with heart failure and the associated societal and payor and hospital costs


  • Hematologic malignancies (e.g., Acute Leukemia, Multiple Myeloma and non-Hodgkin Lymphoma)
  • Bone metastases from solid tumors
  • Malignant Melanoma
  • Colorectal Cancers
  • Immune cytopenias
  • Supportive care


  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Dermatologic diseases with a focus on Psoriasis
  • Other inflammatory diseases including asthma and inflammatory bowel disease
  • Broader topics in immunology and autoimmunity
  • Education about the biosimilar approval pathway, biologic manufacturing and biosimilar development
  • Policy questions related to biosimilars including naming and interchangeability


  • Anemia associated with CKD-treatment, consequences, transfusion
  • CKD Mineral and Bone Disorder – pathogenesis, consequences, treatment
  • Emerging data (clinical and basic research)
  • Quality improvement in the care of patients with renal disease
  • Healthcare disparities
  • Emerging trends in pharmacoeconomics and healthcare policy research pertaining to CKD


Education on Migraine disease states and areas of interest:

  • Promote disease awareness, treatment and education of clinicians, researchers and patients in the area of migraine
  • Identify appropriate patients in the area of migraine
  • Highlight patient related outcomes in Migraine
  • Focus on research of methodologies (pathophysiology, genetic, neuro-pharmacy and chemical biomarkers in migraine


  • ACPE Accredited programs that advance the  field of Pharmacy
  • New areas for professional development in
    • Oncology
    • Hematology
    • Bone
    • Nephrology
    • Inflammation
    • Cardiology
    • Biosimilars

Process Development

Programs that support awareness and education of researchers, students and clinicians in the fields involved in process development, of large molecules, oral parenterals and other novel therapeutics:

    • Candidate and molecule selection
    • Manufacture and characterization (upstream and downstream, synthetic) of drug substance
    • Manufacture and characterization of drug product
    • Device development
    • Quality target product profile and identification of critical quality attributes
    • Society activities involved in education, career development, and scientific exchange in process, product, and device development

Translational Sciences

Programs that support awareness and education of clinicians, researchers and patients in the following areas:

  • Comparative Biology and Safety Sciences
  • Medical Sciences
  • Pharmacokinetics and Drug Metabolism
  • Advance field of Translational Sciences focusing on new areas for professional development
  • Education and training of students through didactic and experiential opportunities
  • Society activities consistent with the above stated topics and areas of interest

Overview of IME Funding Application Process

Amgen is dedicated to making the application process simple and straightforward. Amgen will send an email confirmation upon receipt of your application and documentation.

IME Application Requirements

Amgen's IME funding application process includes:

    Requests for Independent Medical Education funding must be submitted according to the schedule below:

    Application Period Decision will be Communicated: Start date of Program/Activity*
    February 15, 2016 – April 1, 2016 No later than 45 days prior to the program start date July 1, 2016 – December 31 ,2016
    August 1, 2016 – September 16, 2016 No later than 45 days prior to the program start date January 1, 2017 – June 30, 2017

    * Amgen requires that an agreement is fully executed prior to the start date of the program content development or activity. Please plan ahead to ensure the decision and contract execution can be completed to meet your deadline.

  • Requests that are received after an application period has closed will not be considered and will need to be resubmitted during the next application period if the start date for the program qualifies. 
  • Attachment of the following required documents (in .pdf format) to the application:
    • Letter of Request on the requesting organization's letterhead which includes the following:
      • Must be addressed to Amgen
      • Signed and Dated
      • Program title, date(s), and location(s)
      • Description of the proposed activity
      • Identification of the target audience and projected number of attendees
      • Name of accrediting body and accredited provider, including type and number of medical education credits offered for the proposed activity (program MUST be accredited)
      • If applicable, identification of co-requesting organization(s), medical education partner(s), and/or logistical partner. Please include contact information for these organizations.
    • Needs Assessment (can be included in the Letter of Request)
    • Educational Objectives (can be included in the Letter of Request)
    • Agenda (draft acceptable)
    • Full Program Budget
    • Amgen/ Requested Amount Budget
      (Please Note: Amgen does not prohibit organizers from serving meals at IME events; however, Amgen's IME funds cannot be used to provide meals at IME events)
    • Current IRS W9 form (must be signed and dated within the last 12 months)

Please note that submitting a request does not guarantee you and/or your organization will receive IME funding.

Eligibility Criteria - Important Application Considerations

Independent Medical Education supported by Amgen in the U.S. MUST be:

  • Provided by a United States based accredited provider (e.g. ACCME, ACPE, ANCC) or other organizations authorized by state law to award continuing medical education credits.
  • Paid to a United States based organization

It is important to note:

  • Amgen will not provide IME funding for:
    • Individuals
    • Requests for payments to Individuals
    • Fellowships
    • Overhead Expenses
    • General Operating Expenses
    • Entertainment Expenses
    • Awards/ Travel Awards
    • Costs of travel, lodging, or other personal expenses of non-faculty individuals attending IME, either directly to the individuals participating in the event or indirectly to the event's provider. Funding cannot be used to compensate participants for time spent at the IME event.
    • Meals
      • Amgen does not prohibit organizers from serving meals at IME events; however, Amgen's IME funds shall not be used to provide meals at IME events.
  • Amgen's support for IME programs that meet the Eligibility Criteria is compliant with federal and state laws, as well as guidelines that govern such activities.
  • Amgen commercial staff, including field staff, is not involved in decisions to fund IME programs. For more information regarding Amgen's interactions with healthcare professionals and other customers, (click here).
  • Responsibility and control over the selection, content, faculty, educational methods, materials, and venue for an independent medical education event belongs solely to the organizers of the event in accordance with the accredited provider's guidelines. Amgen will not provide any advice or guidance to the accredited independent medical education provider (even if asked) regarding the content or faculty for any Independent Medical Education program.
  • IME funding decisions will not take into account the current or potential customer status of the IME requestor.
  • Amgen requires that a fully-executed agreement, signed by the requesting IME Provider and Amgen be completed prior to the commencement of the IME program.
  • For funding requests approved by Amgen, the IME funding recipient is required to confirm the completion of the activity and provide documentation of how the funds were used within 60 days after the completion of the independent medical education activity. Documentation should be sent to hccime@amgen.com for reconciliation.

Please note that submitting a request does not guarantee you and/or your organization will receive IME funding.